These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24934297)

  • 1. Light obscuration measurements of highly viscous solutions: sample pressurization overcomes underestimation of subvisible particle counts.
    Weinbuch D; Jiskoot W; Hawe A
    AAPS J; 2014 Sep; 16(5):1128-31. PubMed ID: 24934297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods.
    Hawe A; Schaubhut F; Geidobler R; Wiggenhorn M; Friess W; Rast M; de Muynck C; Winter G
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1084-7. PubMed ID: 23454051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
    Nishi H; Mathäs R; Fürst R; Winter G
    J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
    Werk T; Volkin DB; Mahler HC
    Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis.
    Zölls S; Gregoritza M; Tantipolphan R; Wiggenhorn M; Winter G; Friess W; Hawe A
    J Pharm Sci; 2013 May; 102(5):1434-46. PubMed ID: 23463514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.
    Kiyoshi M; Shibata H; Harazono A; Torisu T; Maruno T; Akimaru M; Asano Y; Hirokawa M; Ikemoto K; Itakura Y; Iwura T; Kikitsu A; Kumagai T; Mori N; Murase H; Nishimura H; Oda A; Ogawa T; Ojima T; Okabe S; Saito S; Saitoh S; Suetomo H; Takegami K; Takeuchi M; Yasukawa H; Uchiyama S; Ishii-Watabe A
    J Pharm Sci; 2019 Feb; 108(2):832-841. PubMed ID: 30121316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of subvisible particle formation during the filling pump operation of a monoclonal antibody solution.
    Nayak A; Colandene J; Bradford V; Perkins M
    J Pharm Sci; 2011 Oct; 100(10):4198-204. PubMed ID: 21698601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to reducing subvisible particle counts in lyophilized parenteral formulations.
    Gupta PK; Porembski E; Williams NA
    J Pharm Sci Technol; 1994; 48(1):30-7. PubMed ID: 8004415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of shear and extensional viscosities on atomization of Newtonian and non-Newtonian fluids in ultrasonic inhaler.
    Broniarz-Press L; Sosnowski TR; Matuszak M; Ochowiak M; Jabłczyńska K
    Int J Pharm; 2015 May; 485(1-2):41-9. PubMed ID: 25735665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subvisible Particle Analysis of 17 Monoclonal Antibodies Approved in China Using Flow Imaging and Light Obscuration.
    Guo S; Yu C; Guo X; Jia Z; Yu X; Yang Y; Guo L; Wang L
    J Pharm Sci; 2022 Apr; 111(4):1164-1171. PubMed ID: 34551350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle shape effects on subvisible particle sizing measurements.
    Cavicchi RE; Carrier MJ; Cohen JB; Boger S; Montgomery CB; Hu Z; Ripple DC
    J Pharm Sci; 2015 Mar; 104(3):971-87. PubMed ID: 25446188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Governing the Accuracy of Subvisible Particle Counting Methods.
    Ríos Quiroz A; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV
    J Pharm Sci; 2016 Jul; 105(7):2042-52. PubMed ID: 27287519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Taking Subvisible Particle Quantitation to the Limit: Uncertainties and Statistical Challenges With Ophthalmic Products for Intravitreal Injection.
    Gühlke M; Hecht J; Böhrer A; Hawe A; Nikels F; Garidel P; Menzen T
    J Pharm Sci; 2020 Jan; 109(1):505-514. PubMed ID: 31682829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring Subvisible Particles in Protein Formulations Using a Modified Light Obscuration Sensor with Improved Detection Capabilities.
    Ríos Quiroz A; Québatte G; Stump F; Finkler C; Huwyler J; Schmidt R; Mahler HC; Koulov AV; Adler M
    Anal Chem; 2015 Jun; 87(12):6119-24. PubMed ID: 26001042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
    Gervais D; Corn T; Downer A; Smith S; Jennings A
    AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subvisible Particulate Contamination in Cell Therapy Products-Can We Distinguish?
    Vollrath I; Mathaes R; Sediq AS; Jere D; Jörg S; Huwyler J; Mahler HC
    J Pharm Sci; 2020 Jan; 109(1):216-219. PubMed ID: 31521641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable Threshold Method for Determining the Boundaries of Imaged Subvisible Particles.
    Cavicchi RE; Collett C; Telikepalli S; Hu Z; Carrier M; Ripple DC
    J Pharm Sci; 2017 Jun; 106(6):1499-1507. PubMed ID: 28209364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
    Sharma DK; Oma P; Pollo MJ; Sukumar M
    J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of fast and conservative freeze-drying on product quality of protein-mannitol-sucrose-glycerol lyophilizates.
    Horn J; Schanda J; Friess W
    Eur J Pharm Biopharm; 2018 Jun; 127():342-354. PubMed ID: 29522899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.